Literature DB >> 23525952

Experimental assessment of temperature influence on miriplatin and cisplatin iodized-oil suspension viscosity.

Takaaki Hasegawa1, Haruyuki Takaki, Takashi Yamanaka, Masashi Fujimori, Atsuhiro Nakatsuka, Junji Uraki, Tomomi Yamada, Hajime Sakuma, Koichiro Yamakado.   

Abstract

PURPOSE: To evaluate differences in the viscosity of a platinum iodized-oil suspension on the kind of platinum agent and temperature.
MATERIALS AND METHODS: Viscosities of a 70 mg miriplatin and 3.5 ml iodized-oil suspension (MO suspension) and that of 100 mg cisplatin and 10 ml iodized-oil suspension (CO suspension) were evaluated at three temperatures: 25, 37, and 50 °C. Iodized-oil was used as the control. Each liquid was injected into a capillary tube and allowed to drip separately. The liquid transit time was measured, and the viscosity of each liquid was calculated at each temperature.
RESULTS: The viscosity of each liquid decreased as the temperature increased: 43.3 ± 0.5, 39.2 ± 0.7, and 34.7 ± 0.6 mPa s for MO suspension, 41.3 ± 0.2, 36.9 ± 0.3, and 32.7 ± 0.9 mPa s for CO suspension, and 40.5 ± 0.2, 36.8 ± 0.2, and 33.8 ± 0.7 mPa s for iodized-oil at 25, 37, and 50 °C, respectively. The MO suspension group viscosity was significantly higher than that of the CO suspension group (p < 0.05) and the control (p < 0.05). Significant differences were found in viscosities among groups divided by temperature (25 °C-group vs. 37 °C-group, p < 0.05; 37 °C-group vs. 50 °C-group, p < 0.05).
CONCLUSION: The viscosity of the platinum iodized-oil suspension can be adjusted by changing temperature.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23525952     DOI: 10.1007/s11604-013-0201-0

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  15 in total

1.  Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma.

Authors:  Shiro Miyayama; Masashi Yamashiro; Yoshihiro Shibata; Masahiro Hashimoto; Miki Yoshida; Kazunobu Tsuji; Fumihito Toshima; Osamu Matsui
Journal:  Jpn J Radiol       Date:  2012-01-07       Impact factor: 2.374

2.  Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature.

Authors:  Yasunobu Takaki; Toshio Kaminou; Masanobu Shabana; Takashi Ihaya; Kenji Otsubo; Toshihide Ogawa
Journal:  Hepatogastroenterology       Date:  2008 Jan-Feb

3.  Clinical evaluation of hepatic artery embolization: comparison between Gelfoam and Lipiodol with anticancer agent.

Authors:  Y Yamashita; M Takahashi; N Fujimura; M Kan
Journal:  Radiat Med       Date:  1987 May-Jun

4.  Transcatheter oily chemoembolization of hepatocellular carcinoma.

Authors:  H Nakamura; T Hashimoto; H Oi; S Sawada
Journal:  Radiology       Date:  1989-03       Impact factor: 11.105

5.  Comparison of the anti-tumor effects of two platinum agents (miriplatin and fine-powder cisplatin).

Authors:  Shobu Watanabe; Norihisa Nitta; Shinichi Ohta; Akinaga Sonoda; Hideji Otani; Yuki Tomozawa; Ayumi Nitta-Seko; Keiko Tsuchiya; Toyohiko Tanka; Masashi Takahashi; Kiyoshi Murata
Journal:  Cardiovasc Intervent Radiol       Date:  2011-05-17       Impact factor: 2.740

6.  Clinical utility of transarterial infusion chemotherapy using cisplatin-lipiodol emulsion for unresectable hepatocellular carcinoma.

Authors:  Tetsuya Beppu; Kazushi Sugimoto; Katsuya Shiraki; Masahiko Tameda; Yuji Inagaki; Suguru Ogura; Chika Kasai; Satoko Kusagawa; Keiichiro Nojiri; Misao Yoneda; Hiroyuki Fuke; Norihiko Yamamoto; Yoshiyuki Takei; Masashi Fujimori; Takaaki Hasegawa; Takashi Yamanaka; Junichi Uraki; Masataka Kashima; Haruyuki Takaki; Atsuhiro Nakatsuka; Koichiro Yamakado; Kan Takeda
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

Review 7.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

8.  Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis.

Authors:  N Nakao; H Uchida; K Kamino; Y Nishimura; H Ohishi; Y Takayasu; K Miura
Journal:  Cardiovasc Intervent Radiol       Date:  1994 Mar-Apr       Impact factor: 2.740

9.  Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy.

Authors:  Koichiro Yamakado; Atsuhiro Nakatsuka; Haruyuki Takaki; Hajime Yokoi; Masanobu Usui; Hiroyuki Sakurai; Shuji Isaji; Katsuya Shiraki; Hiroyuki Fuke; Shinji Uemoto; Kan Takeda
Journal:  Radiology       Date:  2008-02-27       Impact factor: 11.105

10.  A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma.

Authors:  Takuji Okusaka; Hiroshi Kasugai; Hiroshi Ishii; Masatoshi Kudo; Michio Sata; Katsuaki Tanaka; Yasukazu Shioyama; Kazuaki Chayama; Hiromitsu Kumada; Masaharu Yoshikawa; Toshihito Seki; Hidetugu Saito; Naoaki Hayashi; Keiko Shiratori; Kiwamu Okita; Isao Sakaida; Masao Honda; Yukio Kusumoto; Takuya Tsutsumi; Kenji Sakata
Journal:  Invest New Drugs       Date:  2011-12-21       Impact factor: 3.850

View more
  4 in total

1.  Clinical utility of radiofrequency ablation following transarterial injection of miriplatin-iodized oil suspension in small hepatocellular carcinoma.

Authors:  Ken Nakajima; Takashi Yamanaka; Atsuhiro Nakatsuka; Takaki Haruyuki; Masashi Fujimori; Yuichi Sugino; Naritaka Matsushita; Hajime Sakuma; Shuji Isaji; Yoshiyuki Takei; Koichiro Yamakado
Journal:  Jpn J Radiol       Date:  2016-07-25       Impact factor: 2.374

2.  Improved efficacy of transcatheter arterial chemoembolization using warmed miriplatin for hepatocellular carcinoma.

Authors:  Daisuke Yasui; Satoru Murata; Shiro Onozawa; Takahiko Mine; Tatsuo Ueda; Fumie Sugihara; Chiaki Kawamoto; Eiji Uchida; Shin-ichiro Kumita
Journal:  Biomed Res Int       Date:  2014-09-08       Impact factor: 3.411

3.  Combination Therapy by Transarterial Injection of Miriplatin-Iodized Oil Suspension with Microwave Ablation for Medium-Sized Hepatocellular Carcinoma: the Preliminary Experience.

Authors:  Motoma Kanaya; Noriyuki Miyamoto; Takaaki Fujii; Kyohei Kudo; Naoya Kinota; Hirotaka Kato
Journal:  Interv Radiol (Higashimatsuyama)       Date:  2022-02-04

4.  Effect of transarterial chemoembolization with miriplatin plus epirubicin on local control of hepatocellular carcinoma: a retrospective comparison with miriplatin monotherapy.

Authors:  Naoko Hashimoto; Jin Iwazawa; Shoichi Ohue; Takashi Mitani
Journal:  Onco Targets Ther       Date:  2013-08-01       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.